Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 17/20 | 0.62 |
| ▸ | JAK2 | O60674 | 2/20 | 0.57 |
| ▸ | JAK1 | P23458 | 2/20 | 0.57 |
| ▸ | TYK2 | P29597 | 2/20 | 0.57 |
| ▸ | JAK3 | P52333 | 2/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19010285 | 0.91 | STAT6 (0.56) | STAT6JAK2JAK1TYK2JAK3 | |
| SCHEMBL17021266 | 0.91 | STAT6 (0.52) | STAT6JAK2JAK1TYK2JAK3 | |
| SCHEMBL17021268 | 0.91 | STAT6 (0.51) | STAT6JAK2JAK1TYK2JAK3 | |
| SCHEMBL17021265 | 0.90 | STAT6 (0.61) | STAT6JAK2JAK1TYK2JAK3 | |
| SCHEMBL17021278 | 0.89 | MAPK10 (0.51) | STAT6JAK2JAK1TYK2JAK3 | |
| SCHEMBL17021291 | 0.88 | STAT6 (0.49) | STAT6JAK2JAK1TYK2JAK3 | |
| SCHEMBL17021269 | 0.87 | STAT6 (0.63) | STAT6JAK2JAK1TYK2JAK3 | |
| SCHEMBL2483155 | 0.86 | STAT6 (0.72) | STAT6MAPK9MAPK10 | |
| SCHEMBL17021288 | 0.85 | STAT6 (0.63) | STAT6JAK2JAK1TYK2JAK3 | |
| SCHEMBL17021295 | 0.84 | STAT6 (0.62) | STAT6JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| WO-2015123453-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK2, JAK3 | STAT6 8/4885JAK2 2/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.